A case study in differing approaches to reimbursement approval in Europe and the US.
Does Real World Evidence Matter in Health Technology Assessments?
Context Matters data cited in the Wall Street Journal! Ed Silverman recently spoke with PhRMA's Randy Burkholder, who noted that between 2007 and 2013, cancer medicines were more than three times as likely to receive unfavorable recommendations from UK agency NICE, as compared with other drugs.
pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Research Analyst Daniel Sanchez: "When Measuring European Regulatory Approval, the Timestamp Matters." The article looks at cycle times in regulatory decisions and how they are being measured in the US and Europe. A cycle time measures the time from the date of submission, through date of approval. We noticed that some of the analyses involving the European Medicines Agency (EMA)’s cycle time used an inappropriate endpoint, resulting in cycle times that looked two months shorter than they actually are.
Fierce Biotech recently featured Context Matters in an e-book "Picking Winners: Data Mining for Drug Discovery". Our founder and CEO Yin Ho discusses how biotech and pharma companies are starting to understand the importance of reimbursement data and the insights that can be learned from following these patterns early in the drug development process.
Our Founder and CEO Yin Ho was recently featured in a MedCity News piece asking "What did you learn from your biggest critic?"
FierceBiotechIT recently wrote about our analysis of online data, researched by the team here at Context Matters in collaboration with Pfizer, that found only 7.4% (47 trials) of 650 Phase 3 and Phase 2/3 clinical trials for diabetes treatments included patient-reported outcomes.
From Drug Development through Reimbursement, Context Matters, Inc. is providing Pharmaceutical Companies with the Large Sets of Data needed to Assess Risk and Reward You can read the full article on ceocfointereviews.com
MedCity News recently did a piece about 40 women to watch and included our founder and CEO Yin Ho on the list.
Managed Care recently did an article about our study on the use of the terms "Effectiveness" and "Efficacy" and how they are often used interchangeably or even misused.
Pharma Voice did a recent article on our study about the increased use of PROs in product evaluations in the healthcare industry, and how they may be providing additional insight as to how regulatory agencies and even manufacturers make decisions.
Check out this fantastic article about Context Matters in Crain's NY, focused on NY-based technology companies that are having a big impact on the healthcare industry.